Publications by authors named "Eliso Solomko"

Claim this Profile
I
Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma.
Maria Volkova, Ilya Tsimafeyeu, Anna Olshanskaya, Yulia Khochenkova, Eliso Solomko

Am J Clin Exp Urol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Alexandra Tyulyandina, Daniel Harrison, Wei Yin, Evgenia Stepanova, Dmitry Kochenkov, Eliso Solomko

Invest New Drugs· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28].
Ilya Tsimafeyeu, John Ludes-Meyers, Evgenia Stepanova, Frits Daeyaert, Dmitry Khochenkov, Eliso Solomko

Eur J Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.
Ilya Tsimafeyeu, John Ludes-Meyers, Evgenia Stepanova, Frits Daeyaert, Dmitry Khochenkov, Eliso Solomko

Eur J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis